Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014

Fineline Cube Oct 10, 2022

China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...

Company Deals

Fujian Cosunter to Acquire UDCA Capsules Technology from Ruitailai

Fineline Cube Oct 10, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced plans to enter into a...

Company Drug

Fujian Cosunter Doses First Patient in Phase I Study of COVID-19 Drug GST-HG171

Fineline Cube Oct 10, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the first patient has...

Company Drug

Salubris Pharmaceuticals’ First-in-Class Anti-Tumor Drug SAL008 Accepted by NMPA

Fineline Cube Oct 10, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that a clinical trial filing...

Company Drug

Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer

Fineline Cube Oct 10, 2022

Swiss pharmaceutical giant Roche’s (SWX: ROG) Herceptin (trastuzumab, subcutaneous injection) has been approved in China...

Policy / Regulatory

CDE Releases 63rd Batch of Chemical Generic Reference Preparations

Fineline Cube Oct 10, 2022

The Center for Drug Evaluation (CDE) has released the 63rd batch of chemical generic reference...

Policy / Regulatory

Jiangsu Launches Sunshine Procurement Platform for Drugs and Medical Consumables

Fineline Cube Oct 10, 2022

Jiangsu province has launched its drugs and medical consumables sunshine procurement services website, providing a...

Company Drug

Merck’s Keytruda Gains 9th Indication Approval in China for Hepatocellular Carcinoma

Fineline Cube Oct 10, 2022

US major Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab)...

Company Deals

Convalife and Jointown Partner for Global Drug Development and Commercialization

Fineline Cube Oct 9, 2022

Shanghai-based Convalife Pharmaceuticals has entered into a strategic partnership with fellow Chinese firm Jointown Pharmaceutical...

Company Drug

Eli Lilly’s Retevmo Wins First China Approvals for RET-Driven Cancers

Fineline Cube Oct 9, 2022

Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...

Company Deals

VectorBuilder Raises $56.6M in Series C to Expand Life Science R&D

Fineline Cube Oct 9, 2022

Guangzhou-based VectorBuilder, a genetic engineering specialist incubated by the state-owned Guangzhou Industrial Investment and Capital...

Company Policy / Regulatory

WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions

Fineline Cube Oct 9, 2022

The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...

Company Policy / Regulatory

India Launches Anti-Dumping Investigation Against Chinese Imports of Metronidazole

Fineline Cube Oct 9, 2022

The Union Ministry of Commerce and Industry in India has initiated an anti-dumping investigation into...

Policy / Regulatory

China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval

Fineline Cube Oct 9, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming...

Company Drug

Ark Biosciences’ Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection

Fineline Cube Oct 9, 2022

China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its...

Company Drug

Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC

Fineline Cube Oct 9, 2022

US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...

Company Drug

Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes

Fineline Cube Oct 9, 2022

China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...

Company Drug Medical Device

Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng

Fineline Cube Oct 9, 2022

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...

Company Deals

Shanghai Lange Medtech Partners with Yantai Desheng for Fish-Derived Rotator Cuff Patch

Fineline Cube Oct 9, 2022

China-based Shanghai Lange Medtech Co., Ltd. has entered into a partnership with compatriot firm Yantai...

Company Deals

Roche Boosts China Investment with Additional RMB 250 Million

Fineline Cube Oct 9, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million...

Posts pagination

1 … 617 618 619 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.